Lee S. Rosen, MD - Medical Oncology ...

Dr. Lee Rosen, MD

Claim this profile

UCLA Department of Medicine

Studies Pancreatic Cancer
Studies Solid Tumors
10 reported clinical trials
23 drugs studied

Area of expertise

1Pancreatic Cancer
Lee Rosen, MD has run 6 trials for Pancreatic Cancer. Some of their research focus areas include:
Stage IV
FGFR1 positive
FGFR2 positive
2Solid Tumors
Lee Rosen, MD has run 4 trials for Solid Tumors. Some of their research focus areas include:
Stage IV
Stage III
FGFR1 positive

Affiliated Hospitals

Image of trial facility.
UCLA Department Of Medicine
Image of trial facility.
UCLA

Clinical Trials Lee Rosen, MD is currently running

Image of trial facility.

OBT076

for Advanced Cancer

The purpose of this study is to evaluate OBT076, which is a drug that combines an antibody with an anti-cancer drug. This class of drugs are called Antibody-Drug Conjugates (ADC). Antibodies are normally produced in the human body by the immune system to fight infections but can be designed to target cancer cells and deliver an anti-cancer drug. OBT076 is composed of an antibody that targets the CD205 protein on cancer cells and delivers an anti-cancer drug which can kill them. OBT076 is an "Investigational Drug", which means that it is still being studied and has not yet been approved by the US Food and Drug Administration (FDA), the European Medicines Agency (EMA) or any other regulatory authorities to be prescribed by doctors for the treatment of metastatic or recurrent solid tumors. The use of OBT076 in this study is investigational. This is a Phase I research study designed to look at several dose levels of the study drug to find the highest dose level that is safe and well-tolerated (does not cause unacceptable side effects), and to examine the effects of the study drug in a small group of research participants. The study will also look at the effectiveness of OBT076 as an anti-cancer therapy. Once the optimal dose is determined and safety is assessed, additional research participants will be treated at the optimal dose level to further evaluate safety and effectiveness.
Recruiting1 award Phase 115 criteria
Image of trial facility.

CX-5461

for Solid Cancers

This is an open-label, multi-center, phase 1b study designed to determine a tolerable dose of CX-5461 administered by IV infusion on Day 1 and Day 8 of a 28-day cycle in patients with selected solid tumours and associated mutations for future Phase II trials. The safety and tolerability of CX-5461, preliminary evidence of antitumor effect and the effect of CX-5461 on the Health-Related Quality of Life (HRQoL) will also be evaluated. The study will also evaluate the predictive value of mutational signatures and explore the significance of dynamic changes in ctDNA levels and plasma DNA methylome profiling in this study's exploratory cohort.
Recruiting1 award Phase 110 criteria

More about Lee Rosen, MD

Clinical Trial Related3 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Lee Rosen, MD has experience with
  • Futibatinib
  • NG-350A
  • Pembrolizumab
  • OBT076
  • NG-641 In Combination With Nivolumab
  • FOLFIRI

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Lee Rosen, MD specialize in?
Is Lee Rosen, MD currently recruiting for clinical trials?
Are there any treatments that Lee Rosen, MD has studied deeply?
What is the best way to schedule an appointment with Lee Rosen, MD?
What is the office address of Lee Rosen, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security